Geroprotectors as a therapeutic strategy for COPD – where are we now?
Joanna Miłkowska-Dymanowska,1,2 Adam J Białas,1,2 Joanna Makowska,2,3 Aleksandra Wardzynska,2,4 Paweł Górski,1,2 Wojciech J Piotrowski1,2 1Department of Pneumology and Allergy, 1st Chair of Internal Medicine, 2Healthy Aging Research Centre, 3Department of Rheumatology, 4Department of Imm...
Guardado en:
Autores principales: | Miłkowska-Dymanowska J, Białas AJ, Makowska J, Wardzynska A, Górski P, Piotrowski WJ |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2017
|
Materias: | |
Acceso en línea: | https://doaj.org/article/18d3b333edd144d7865d3aff83864e3e |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Eosinopenia and neutrophil-to-lymphocyte count ratio as prognostic factors in exacerbation of COPD
por: Tomasz Karauda, et al.
Publicado: (2021) -
COPD: What the anaesthetist should know
por: M. L. Wong
Publicado: (2016) -
COPD sleep phenotypes: Genesis of respiratory failure in COPD
por: Sameer Vaidya, et al.
Publicado: (2021) -
Statin use and risk of diabetes mellitus
por: Oksana Mikhailovna Drapkina, et al.
Publicado: (2012) -
The leukocyte telomere length, single nucleotide polymorphisms near TERC gene and risk of COPD
por: Tanya Tacheva, et al.
Publicado: (2021)